The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis

被引:39
|
作者
Teng, Liu [1 ]
Feng, Yu Chen [2 ]
Guo, Su Tang [3 ,5 ]
Wang, Pei Lin [1 ]
Qi, Teng Fei [1 ]
Yue, Yi Meng [1 ]
Wang, Shi Xing [1 ]
Zhang, Sheng Nan [1 ]
Tang, Cai Xia [1 ]
La, Ting [4 ,6 ]
Zhang, Yuan Yuan [4 ,6 ]
Zhao, Xiao Hong [4 ,6 ]
Gao, Jin Nan [7 ]
Wei, Li Yuan [7 ]
Zhang, Didi [8 ]
Wang, Jenny Y. [9 ]
Shi, Yujie [10 ]
Liu, Xiao Ying [1 ]
Li, Jin Ming [1 ]
Cao, Huixia [11 ]
Liu, Tao [1 ,9 ]
Thorne, Rick F. [1 ,4 ,6 ]
Jin, Lei [1 ,2 ]
Shao, Feng-Min [11 ]
Zhang, Xu Dong [1 ,4 ,6 ]
机构
[1] Henan Prov Peoples Hosp, Translat Res Inst, Zhengzhou, Henan, Peoples R China
[2] Zhengzhou Univ, Peoples Hosp Zhengzhou Univ, Acad Med Sci, Zhengzhou, Henan, Peoples R China
[3] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia
[4] Shanxi Canc Hosp, Dept Mol Biol, Taiyuan, Shanxi, Peoples R China
[5] Shanxi Canc Inst, Dept Mol Biol, Taiyuan, Shanxi, Peoples R China
[6] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia
[7] Shanxi Bethune Hosp, Dept Breast Surg, Taiyuan, Shanxi, Peoples R China
[8] John Hunter Hosp, Hunter New England Hlth, Dept Orthopaed, New Lambton, NSW, Australia
[9] Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia
[10] Zhengzhou Univ, Peoples Hosp, Henan Prov Peoples Hosp, Dept Pathol, Zhengzhou, Peoples R China
[11] Zhengzhou Univ, Peoples Hosp, Henan Prov Peoples Hosp, Dept Nephrol, Zhengzhou, Henan, Peoples R China
基金
英国医学研究理事会; 中国国家自然科学基金;
关键词
LONG NONCODING RNA; COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMA; SILENCING MEDIATOR; COLORECTAL-CANCER; GENE-EXPRESSION; PROTEIN-LEVELS; RETINOIC ACID; BREAST-CANCER; SMRT;
D O I
10.1038/s41467-021-24099-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Genomic amplification of the distal portion of chromosome 3q, which encodes a number of oncogenic proteins, is one of the most frequent chromosomal abnormalities in malignancy. Here we functionally characterise a non-protein product of the 3q region, the long noncoding RNA (lncRNA) PLANE, which is upregulated in diverse cancer types through copy number gain as well as E2F1-mediated transcriptional activation. PLANE forms an RNA-RNA duplex with the nuclear receptor co-repressor 2 (NCOR2) pre-mRNA at intron 45, binds to heterogeneous ribonucleoprotein M (hnRNPM) and facilitates the association of hnRNPM with the intron, thus leading to repression of the alternative splicing (AS) event generating NCOR2-202, a major protein-coding NCOR2 AS variant. This is, at least in part, responsible for PLANE-mediated promotion of cancer cell proliferation and tumorigenicity. These results uncover the function and regulation of PLANE and suggest that PLANE may constitute a therapeutic target in the pan-cancer context. Genomic amplification of chromosome 3q often encodes proteins that contribute to cancer development. Here the authors identify a non-coding product of the 3q region, the lncRNA PLANE that promotes tumorigenesis through the deregulation of transcriptional corepressor NCOR2 pre-mRNA splicing.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis
    Liu Teng
    Yu Chen Feng
    Su Tang Guo
    Pei Lin Wang
    Teng Fei Qi
    Yi Meng Yue
    Shi Xing Wang
    Sheng Nan Zhang
    Cai Xia Tang
    Ting La
    Yuan Yuan Zhang
    Xiao Hong Zhao
    Jin Nan Gao
    Li Yuan Wei
    Didi Zhang
    Jenny Y. Wang
    Yujie Shi
    Xiao Ying Liu
    Jin Ming Li
    Huixia Cao
    Tao Liu
    Rick F. Thorne
    Lei Jin
    Feng-Min Shao
    Xu Dong Zhang
    Nature Communications, 12
  • [2] The pan-cancer lncRNA PLANE promotes cancer pathogenesis through regulating an alternative splicing program
    Feng, Yuchen
    La, Ting
    Zhang, Yuanyuan
    Zhao, Xiaohong
    Sokulsky, Leon
    Jin, Lei
    Zhang, Xu Dong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 15 - 15
  • [3] A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients
    Cheng, Rui
    Xiao, Lixing
    Zhou, Wenyang
    Jin, Xiyun
    Xu, Zhaochun
    Xu, Chang
    Wang, Pingping
    Luo, Meng
    Wang, Mengyun
    Ma, Kexin
    Cao, Huimin
    Huang, Yan
    Lin, Xiaoyu
    Pang, Fenglan
    Li, Yiqun
    Jiang, Qinghua
    ONCOGENE, 2021, 40 (35) : 5441 - 5450
  • [4] A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients
    Rui Cheng
    Lixing Xiao
    Wenyang Zhou
    Xiyun Jin
    Zhaochun Xu
    Chang Xu
    Pingping Wang
    Meng Luo
    Mengyun Wang
    Kexin Ma
    Huimin Cao
    Yan Huang
    Xiaoyu Lin
    Fenglan Pang
    Yiqun Li
    Qinghua Jiang
    Oncogene, 2021, 40 : 5441 - 5450
  • [5] AS-CMC: a pan-cancer database of alternative splicing for molecular classification of cancer
    Park, Jiyeon
    Lee, Jin-Ok
    Lee, Minho
    Chung, Yeun-Jun
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [6] AS-CMC: a pan-cancer database of alternative splicing for molecular classification of cancer
    Jiyeon Park
    Jin-Ok Lee
    Minho Lee
    Yeun-Jun Chung
    Scientific Reports, 12 (1)
  • [7] AS-CMC: a pan-cancer database of alternative splicing for molecular classification of cancer
    Park, Jiyeon
    Lee, Jin-Ok
    Lee, Minho
    Chung, Yeun-Jun
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 247 - 247
  • [8] Pan-cancer analysis of alternative splicing patterns and association to genomic aberrations
    Hayrynen, Sergei
    Nykter, Matti
    CANCER RESEARCH, 2016, 76
  • [9] MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors
    Urbanski, Laura
    Brugiolo, Mattia
    Park, SungHee
    Angarola, Brittany L.
    K. Leclair, Nathan
    Yurieva, Marina
    Palmer, Phil
    Sahu, Sangram Keshari
    Anczukow, Olga
    CELL REPORTS, 2022, 41 (08):
  • [10] Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers
    Yangjun Zhang
    Libin Yan
    Jin Zeng
    Hui Zhou
    Haoran Liu
    Gan Yu
    Weimin Yao
    Ke Chen
    Zhangqun Ye
    Hua Xu
    Oncogene, 2019, 38 : 6678 - 6695